Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441408 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 3
- Development phase
- 2,277
- Enrollment target
NCT07441408 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 2,277 participants.
The verdict
NCT07441408, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,277 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Interventions
- DRUG BMS-986278
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,277 participants |
| Start Date | 2026-12-16 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441408
The ClinicalTrials.gov registry entry for NCT07441408 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 2,277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986278 is the first listed.
NCT07441408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07441408 about?
NCT07441408 is a clinical study titled "Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis". The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
What is the current status of trial NCT07441408?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 2,277 participants. The study started on 2026-12-16. Estimated completion is 2030-03-30.
What interventions are being tested in trial NCT07441408?
The interventions under investigation include: BMS-986278 (DRUG).
Who is sponsoring clinical trial NCT07441408?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.